Navigation Links
AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
Date:5/8/2012

safety study of patients with post-operative pain following hip and knee replacement surgeries, with top-line data expected in late 2012 or early 2013.

Financial OutlookAcelRx anticipates that research and development expenses for the remainder of 2012 and into 2013 will increase significantly as AcelRx seeks to execute and complete the Phase 3 clinical development program of ARX-01.  Development of ARX-04 through Phase 2 clinical work and Phase 3 preparatory work is fully funded by a grant from USAMRMC.  The development of ARX-04 beyond Phase 2 and initial preparations for Phase 3 is dependent on identification of sources of additional funding. Additionally, AcelRx anticipates modest increases in general and administrative expenses due to costs associated with operating as a public company and expansion of its corporate infrastructure to support ongoing development of its product candidates.

AcelRx believes its current cash, cash equivalents and investments are sufficient to fund operations into the first quarter of 2013.

About AcelRx Pharmaceuticals, Inc. Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.  AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is currently in Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps.  AcelRx has two additional product candidates which have completed Phase 2
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 Roughly three-quarters of pharmacists ... substituting an interchangeable biosimilar for its branded biologic ... nonproprietary name, according to a survey published in ... Journal of Managed Care & Specialty Pharmacy (JMCP). ... of pharmacists would feel as confident if the ...
(Date:2/27/2015)... 2015  Pomerantz LLP is investigating claims on behalf ... "Company") (NASDAQ: VTAE ).  Such investors are ... rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... officers and/or directors have violated Sections 10(b) and 20(a) ... On February 27, 2015, the Company announced that ...
(Date:2/27/2015)... 2015 - ... di monitoraggio dell,infarto congestizio (CHF - Congestive Heart ...     Vectorious Medical Technologies, ... per il monitoraggio cardiaco destinato a pazienti affetti ... aver concluso una raccolta di finanziamenti per 5 ...
Breaking Medicine Technology:Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2
... Sept. 23, 2011 Masimo ... U.S. Department of Health & Human Services (HHS) has ... pulse oximetry as a national newborn screening standard.  In ... for CHD detection, published online in the Lancet ...
... HILL, N.C., Sept. 23, 2011 A pharmaceutical company,s ... cannibalization when introducing a new brand in a space ... more than two-thirds of companies, the most frequent changes ... product through activities, such as professional relations, promotional literature, ...
Cached Medicine Technology:U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 2U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 3U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 4U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 5U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 6U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 7U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 8U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 9U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 10Pharmaceutical Marketing Strategy Balances Support Between New & Established Products in the Same Indication 2
(Date:3/1/2015)... IL (PRWEB) March 01, 2015 Ticket Down ... Dead in Chicago at Soldier Field. Deadheads have ... announced in January. , Grateful Dead was formed 50 years ... they were together as one until the untimely death of ... for combining different genres including blues, reggae, rock, bluegrass, folk, ...
(Date:3/1/2015)... ERISAPros is pleased to announce the ... professional staff of its Compliance Department. , Evelyn King, ... University-Mortiz College of Law. Prior to joining ERISAPros, Evelyn ... Fortune 500 companies as well as several privately held ... experiences range from benefit plan design, vendor management, administrative ...
(Date:3/1/2015)... (PRWEB) February 28, 2015 CrossFit Attollo is ... they are offering a special discount to new members. ... up for a three month contract will receive their fourth ... individually would cost members $440. The three month contract ... month, and then the fourth month comes in at only ...
(Date:2/28/2015)... 01, 2015 Heart diseases are on ... percent of urban adult population and 5 percent of ... diseases and 20-30 percent of them require specialized investigation ... and coronary vascular diseases (CVD). , A division of ... market research report titled “Indian Coronary Stent Market Forecast ...
(Date:2/28/2015)... IL (PRWEB) February 28, 2015 With ... Chunk Fitness has added an additional exercise to their ... the oblique exercise is most commonly known as, is ... , “Rope Pulls” are executed in a relatively safe ... fitness and strength levels. The full description of “Rope ...
Breaking Medicine News(10 mins):Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Ticket Prices in Chicago at Soldier Field for 4th of July Weekend Celebration 2Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3
... Calif., Oct. 24 The Blue Cross of,California Foundation ... aid,in the disaster relief in Southern California. The funds ... to California families who have,been directly affected by the ... the health and safety of our members and the,communities ...
... declines or local extinctions in a majority of species ... study from the University of Illinois shows that parasites ... species in fragmented forests. This is the first study ... of infectious parasites on animals already stressed by disturbances ...
... Center To, Evaluate Numerous Possible Lawsuits Related to Defective ... Leads Used With Medtronic Implantable Defibrillators, NEW YORK, ... implanted into hundreds of thousands of,people, leaving all of them ... As a result of this, Parker Waichman Alonso LLP has ...
... Elder Care Company provides FREE assistance for families seeking ... senior living and nursing homes guidance, ... nation,s largest,referral service of senior care options, is available for ... works with,over 2,000 senior housing properties in the state of ...
... Sullivan, M.D., Former Secretary of HHS, Senator Norm Coleman, ... McClellan, M.D., Ph.D., and,members of the patient and medical ... scientific evidence countering the United States Preventive, Services Task ... ARLINGTON, Va., Oct. 24 The Potomac,Institute for ...
... cancers are not alike, most share common causes, whether ... faulty biochemical signaling pathway. For that reason, drugs developed ... many others. Increasingly, researchers are discovering ways of combining ... the targets of already-approved targeted therapeutics. , Today ...
Cached Medicine News:Health News:Blue Cross of California Foundation Donates $50,000 to American Red Cross 2Health News:Parasites a key to the decline of red colobus monkeys in forest fragments 2Health News:Parasites a key to the decline of red colobus monkeys in forest fragments 3Health News:Medtronic Sprint Fidelis Defibrillator Lead Lawsuit Claims Center Opens to Aid Victims 2Health News:Medtronic Sprint Fidelis Defibrillator Lead Lawsuit Claims Center Opens to Aid Victims 3Health News:A Place for Mom Offers Free Assistance to California Seniors Displaced by Wildfires 2Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 2Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 3Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 4Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 5Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 2Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 3Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 4Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 5Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 6Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 7Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 8
... The DTX Series Multimode Detectors ... a variety of application and automation ... and absorbance measurements on the same ... as standalone instruments or can be ...
... Screening (HTS), Analyst HT smoothes the ... sharing all the detection modalities and ... intensity, fluorescence polarization, time-resolved fluorescence, luminescence, ... into robotic environments, including those from ...
... right features for assay development and ... control. Reduces the inevitable transfer time ... Specifically developed to meet the challenges ... delivers unparalleled detection performance for Fluorescence ...
... flexible multifunction plate reader that offers four ... intensity, time-resolved fluorescence, high-perfomance luminescence and absorbance. ... injectors that deliver reagent at the point ... assays can be performed easily and allowing ...
Medicine Products: